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Abstract
Background: Plasma or serum zinc concentration (PZC or SZC) is the primary measure of zinc status, but accurate
sampling requires controlling for hemolysis to prevent leakage of zinc from erythrocytes. It is not established how much
hemolysis can occur without changing PZC/SZC concentrations.
Objective: This study determines a guideline for the level of hemolysis that can significantly elevate PZC/SZC.
Methods: The effect of hemolysis on PZC/SZC was estimated by using standard hematologic variables and mineral
content. The calculated hemolysis threshold was then compared with results from an in vitro study and a population
survey. Hemolysis was assessed by hemoglobin and iron concentrations, direct spectrophotometry, and visual
assessment of the plasma or serum. Zinc and iron concentrations were determined by inductively coupled plasma
spectrometry.
Results: A 5% increase in PZC/SZC was calculated to result from the lysis of 1.15% of the erythrocytes in whole blood,
corresponding to ;1 g hemoglobin/L added into the plasma or serum. Similarly, the addition of simulated hemolysate to
control plasma in vitro caused a 5% increase in PZCwhen hemoglobin concentrations reached 1.186 0.10 g/L. In addition,
serum samples from a population nutritional survey were scored for hemolysis and analyzed for changes in SZC; samples
with hemolysis in the range of 1–2.5 g hemoglobin/L showed an estimated increase in SZC of 6% compared with
nonhemolyzed samples. Each approach indicated that a 5% increase in PZC/SZC occurs at ;1 g hemoglobin/L in plasma
or serum. This concentration of hemoglobin can be readily identified directly by chemical hemoglobin assays or indirectly
by direct spectrophotometry or matching to a color scale.
Conclusions: A threshold of 1 g hemoglobin/L is recommended for PZC/SZC measurements to avoid increases in zinc
caused by hemolysis. The use of this threshold may improve zinc assessment for monitoring zinc status and nutritional
interventions. J Nutr 2017;147:1218–25.
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Introduction
Zinc is an essential nutrient for normal growth, healthy
pregnancy, and robust immune function. Inadequate zinc leads
to stunting, developmental delays, hypogonadism, susceptibility
to infections, and cognitive dysfunction (1–3). Globally, an
estimated 1.2 billion individuals are at risk of zinc deficiency on
the basis of national food balance sheets, with the highest
prevalence in children <5 y of age (3, 4). To evaluate the zinc
status of a population, nutritional surveys collect data on plasma
zinc concentration (PZC)8 or serum zinc concentration (SZC)
along with dietary information. Interestingly, these studies have
indicated that the prevalence of low circulating zinc is nearly
twice as high as the previous estimates of zinc deficiency from
dietary or stunting data alone (5–7). Thus, the current estimates
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of individuals at risk of zinc deficiency could be considerably
underestimated. The accurate assessment of zinc status bio-
markers such as PZC and SZC is critical for understanding the
true burden of zinc deficiency and evaluating the response to zinc
nutrition intervention programs.
Measuring PZC and SZC requires the acquisition of blood by
venipuncture or finger-stick, followed by rapid and careful
processing to isolate plasma or serum for later analysis. With
any study, there is a potential for variation in the processing and
handling of blood samples, but especially when studies are large,
multicenter, or depend on field sites with limited resources.
Suboptimal blood collection and sample handling can increase
the likelihood of damage to erythrocytes, resulting in some degree
of hemolysis. Hemolysis has the potential to measurably increase
PZC and SZC concentrations because the zinc concentration in
erythrocytes is ;10–20 times that of plasma or serum (8–10).
Hemolysis is widely recognized as a potential source of
contamination or interference for a variety of hematologic
variables, which has been addressed in numerous publications
(11–14). It is also acknowledged that hemolysis could lead to
spurious increases in PZC and SZC (6, 15–19), although there is
little information as to what level of hemolysis creates a concern.
Most studies that reported PZC or SZC have limited or no
detailed description of how hemolysis was categorized. There-
fore, the International Zinc Nutrition Consultative Group and
the Biomarkers of Nutrition for Development Zinc Expert Panel
have simply stated that obviously hemolyzed samples should be
discarded when measuring PZC and SZC (6). More work is
needed to develop evidence-based recommendations on the level
of hemolysis that alters PZC and SZC. This article recommends a
threshold of hemolysis for zinc analysis and compares options for
assessing the degree of hemolysis. It is important to note that
although plasma and serum have important physiologic differ-
ences, there does not appear to be a meaningful difference in zinc
concentration between the 2 (6); consequently, the clinical
reference ranges for PZC/SZC are the same (20). This article
therefore treats PZC and SZC as interchangeable from the
perspective of impact of hemolysis.
Methods
Calculations for hemolysis estimates. The effects of hemolysis levels
on PZC and SZC were estimated by using standard hematologic and
mineral concentration parameters obtained from clinical reference
ranges, specifically PZC and SZC (0.7–1.2 mg/L), plasma and serum
hemoglobin concentration (<0.1mg/L), erythrocyte cell concentration (3.8–
5.73 1012 cells/L), erythrocyte cell volume (80–100 fL/cell), erythrocyte
cell hemoglobin content (27–31 pg/cell), and erythrocyte cell zinc
concentration (10–16 mg/L cell volume) (20). The degree of hemolysis
needed to increase PZC and SZC values was calculated by using the
equation [(A 3 B) O (C 3 D) O E] 3 100 = F, where A is the average
PZC and SZC of the study or population, B is the measure of precision
beyond which zinc values are considered increased over the mean PZC
and SZC, C is the average erythrocyte zinc concentration of the study or
population, D is the average erythrocyte volume (also known as mean
corpuscular volume) of the study or population, and E is the average
erythrocyte concentration (also known as RBC count) of the study or
population. The product (F) of this equation is the percentage of erythrocyte
lysis required to yield the desired increase in PZC and SZC. The concentration
of hemoglobin that corresponds to the determined degree of hemolysis was
calculated according to the equationGO [(A3 B)O (C3 D)] =H, where
A–D represent the same values as above andG is the erythrocyte hemoglobin
concentration (also known as mean corpuscular hemoglobin content). The
product (H) of this equation is the concentration of hemoglobin that
indicates a significant increase in PZC and SZC.
In vitro hemolysis study. Blood samples from 14 healthy participants
(Supplemental Table 1) were purchased from a commercial laboratory
(AllCells LLC). The laboratory prescreened donors for lack of infectious
agents (e.g., HIV, hepatitis B virus, and hepatitis C virus), chronic illness,
and medication or supplement use within the previous 2 wk. Venous
whole blood was collected in trace metal–certified Vacutainers containing
lithium heparin as anticoagulant (BD), inverted several times, and stored
at room temperature until processing within 2 h. Whole blood was
centrifuged at 600 3 g for 15 min at room temperature followed by
immediate removal of the plasma. The plasma was transferred to
polypropylene microtubes (tested free of metal contamination) and
further centrifuged at 30003 g for 5 min at room temperature to remove
any remaining cells and debris. The clarified plasma was then transferred
to new polypropylene microtubes and stored at 280C. For concen-
trated hemolysate, erythrocyte-rich plasma was allowed to gradually
hemolyze over 4 mo at 4C to reduce the formation of precipitate or
insoluble material that could affect mineral concentration. To generate
graded hemolysis, defined amounts of concentrated hemolysate were
added to nonhemolyzed plasma and mixed to uniformity at 6 different
ratios of 0%, 0.1%, 0.25%, 1%, 2.5%, and 10% concentrated
hemolysate volume into control nonhemolyzed plasma volume. Ten
experiments were completed from the participant samples for a total of
60 independent points. Graded hemolysis samples were then analyzed
for hemoglobin and mineral concentrations. The commercial laboratory
also provided basic anthropometric and hematologic donor information,
but no protected health information, so institutional review board (IRB)
registration was not required.
Population nutritional survey. Briefly, whole bloodwas collected from
909 infants at 6–18 mo of age living in Ghana for the 2012–2013 Trial
for Reducing Undernutrition through Modified Feeding study (21).
Blood was collected in trace metal–certified Vacutainers without
anticoagulant (BD) at multiple locations, transported back to a central
storage facility, separated into serum samples, and stored at 280C. In
2016, serum samples were shipped in batch to the Childrens Hospital
Oakland Research Institute for the determination of SZC. At the
Childrens Hospital Oakland Research Institute, serum samples were
thawed, mixed on a vortex for 5 s, and prepared for mineral analysis as
described below. Before proceeding with elemental analysis, each sample
was compared visually to a hemolysis color scale by the same trained
technicians and assigned to 1 of 6 hemolysis levels from 0 to 10 g
hemoglobin/L. Additional description and results from this population-
based study will be described in a future study (S Ghosh, unpublished
data, 2017). The study was monitored by the host institute IRB; no
protected health information was communicated for elemental and
hemolysis analysis, so additional IRB registration was not required.
Mineral analysis. Iron and zinc concentrations were determined by
inductively coupled plasma optimal emission spectrometry (ICP-OES) as
previously described (22, 23). For PZC and SZC, 50- to 100-mL samples
were removed from thawed stocks and processed for mineral analysis.
The ICP-OES was calibrated by using National Institute of Standards
and Technology traceable elemental standards (Sigma-Aldrich) and
validated by using Seronorm Trace Element Levels 1 and 2 reference
material (Sero). The detection range for both iron and zinc was between
0.005 and 5.000 mg/L and the CV for interassay precision was <5%.
Cesium (50 mg/L) was used for ionization suppression, and yttrium
(5 mg/L) was used as an internal standard for all samples. All associated
reagents and plasticware were certified as trace metal free or tested for
trace metal contamination. Iron and zinc concentrations were normal-
ized per plasma or serum volume.
Determination of hemoglobin concentration. Hemolysis is com-
monly quantified by the corresponding amount of hemoglobin released
into the plasma or serum. The concentrations of hemoglobin were
determined by using the following: 1) direct chemical detection of
hemoglobin with the use of Drabkins assay according to standard
protocols (24); 2) indirect chemical detection of hemoglobin with the use
of iron concentration calculated from standard molar ratios (4 mol Fe/1
mol hemoglobin); 3) spectroscopic estimation of hemoglobin by directly
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measuring absorbance of plasma or serum at 540 nm, a major
absorbance peak for hemoglobin; or 4) visual inspection of plasma or
serumwith the use of a hemolysis color scale generated by adding defined
amounts of hemoglobin from a human hemoglobin standard (Point
Scientific) to fresh plasma or serum containing no apparent hemolysis
(hemoglobin <0.2 g/L and no orange-red tint). For spectroscopic
estimation, 100 mL plasma or serum was pipetted into 96-well flat-
bottom polystyrene microplates and measured on a conventional
spectrophotometer with path-length correction (Synergy H1; Biotek
Instruments); background absorbance of empty wells was ;0.05
absorbance units. For visual inspection, 3 independent color scales
were generated in optically clear plastic cuvettes and imaged with a
digital camera. Color was determined by using Adobe Photoshop
Elements color picker tool (version 13.1) with all files converted to
Adobe RGB color profile (with a gamut better matched to human visual
perception) on a computer monitor with a calibrated color spectrum.
Color values were determined by using the color picker tool to aggregate
;50% of the color image with the use of an 8-bit red, green, blue (RGB)
color model. RGB values can be converted to other color models for
printing by using printers with appropriate color-monitoring tools.
Statistical analysis. Graphing, regression, and statistical analysis were
conducted by using Prism software, version 6 (GraphPad Software, Inc.).
For comparisons of 1) in vitro plasma mineral and hemoglobin
concentrations, 2) in vitro plasma zinc and plasma iron concentrations,
and 3) population serum zinc and zinc and serum iron concentrations,
linear regression was used. For comparison of population serum mineral
concentrations with hemolysis range, 1 data point was removed from
both the iron and zinc values because they were >3 SDs from the
hemolysis range groupmean, which left 908 values for each mineral. The
mean serum iron and zinc concentrations for each hemolysis range were
compared by using a 1-factor ANOVA with Dunnetts multiple-
comparison ad hoc test for differences compared with the control
(nonhemolyzed) group. Serum mineral concentration data did not pass
the test for normal distribution (DAgostino and Pearson omnibus test,
a = 0.05), but sample sizes were large enough for the ANOVA model to
be robust. For all of the tests, significance was accepted at P < 0.05.
Results
Effects of hemolysis on PZC or SZC by calculation. The
degree of hemolysis required to increase PZC and SZC was
estimated by using values within the standard hematologic and
mineral concentration reference ranges. To model these calcula-
tions for a population in whom nutrient deficiencies are common,
lower values for each parameter were used. In addition, the
analytical techniques that measure PZC and SZC, including atomic
absorption spectrometry (AAS) or ICP-OES, typically have a
precision of ;5% CV (25). Therefore, the target amount of
hemolysis required to detect an increase in PZC and SZC was
selected as 5%. In practice, the population values or desired precision
may vary, so the parameters can be easily adjusted as needed.
The calculations to determine a threshold level of hemolysis
use the equations described in Methods on the basis of the
following descriptions of each step:
1. Determine the amount of zinc needed to increase PZC and
SZC by 5%. For an average PZC and SZC of 0.7 mg/L, an
additional 0.035 mg Zn/L would be released into the
plasma or serum.
2. Determine the fraction of erythrocyte zinc that would
increase PZC and SZC by 0.035 mg/L. For an average
erythrocyte zinc concentration of 10 mg/L and erythro-
cyte volume of 80 fL/cells, the erythrocyte zinc content
would be 0.8 fg/cell. To release 0.035 mg Zn into the
plasma or serum, the concentration of lysed erythrocytes
would be 4.375 3 1010 cells/L.
3. Determine the level of hemolysis that equates to 4.375 3
1010 erythrocytes/L. For an average erythrocyte concen-
tration of 3.8 3 1012 cells/L, 4.375 3 1010 cells/L
represents 1.15% of the erythrocyte concentration.
4. Determine the concentration of hemoglobin that equates
to 1.15% of erythrocytes. For an average erythrocyte
hemoglobin concentration of 27 pg/cell and an erythro-
cyte concentration of 4.375 3 1010 cells/L, 1.12 g
hemoglobin/L would be released into the plasma or
serum. Because normal plasma or serum concentrations of
hemoglobin are negligible, then 1.12 g hemoglobin/L
represents the actual hemoglobin that would be measured
by lysis of 1.15% of erythrocytes.
Effects of hemolysis on PZC in vitro. To empirically
determine the level of hemolysis that would increase PZC by
5%, concentrated hemolysate was added to nonhemolyzed
plasma followed by hemoglobin and mineral analysis. Ratios of
hemolyzed to nonhemoylzed plasma were chosen both within
and exceeding the clinical reference range for iron (0.5–
1.75 mg/L) and zinc (0.7–1.2 mg/L) concentrations in plasma
or serum (20). Iron concentration increased with the addition of
hemolysate, reaching nearly 3000% of the control value as
hemoglobin concentrations approached 10 g/L (Figure 1A). The
data fit a linear function y = 303.9 (x) + 105.4 with an R2 of
0.918. In contrast, the zinc concentration did not consis-
tently change at lower levels of added hemolysate, but in-
creased modestly only after the hemolysate level reached 1 g
hemoglobin/L in the plasma (Figure 1B). The data fit a linear
function y = 5.233 (x) + 98.80 with an R2 of 0.698. The best-fit
line for the zinc response crossed the level of 5% over baseline
at a hemoglobin concentration of 1.18 6 0.10 g/L, similar to
findings from the calculated values. However, the correlation
between iron and zinc values within the same sample was weak;
the linear function fit the equation y = 17.44 (x) 2 11.86 with
an R2 of 0.274 (Figure 1C).
Effects of hemolysis on SZC in a population study. To test
the hemolysis threshold of 1 g hemoglobin/L, the correlation
between apparent hemolysis level and SZC was examined in
samples obtained in a large population study conducted in
Ghana. SZCs ranged from 0.21 to 1.44 mg/L, with a mean6 SD
of 0.616 0.13 mg/L (Figure 2A). SZCs were low compared with
the reference ranges in the United States, but this was expected
because 15–25% of the population in Ghana is estimated to be
at risk of zinc inadequacy (4). Mineral analysis was conducted
by ICP-OES, so serum iron concentrations were also deter-
mined. Serum iron concentrations ranged from 0.36 to 72 mg/L,
with a mean 6 SD of 3.92 6 3.76 mg/L (Figure 2A). Many
(;40%) samples exceeded the clinical reference range for serum
iron concentration and had a visible tint ranging from light
orange to dark red, suggesting elevated hemolysis levels in those
samples. When the mineral values were plotted together, the
data fit a linear function y = 6.087 (x) + 0.1793 with an R2 of
0.104, indicating a weak correlation between serum iron and
zinc values.
The samples were then divided into 6 groups on the basis of
apparent hemolysis level: 0–0.2, 0.2–0.5, 0.5–1, 1–2.5, 2.5–5,
and 5–10 g hemoglobin/L. Compared with the 0–0.2-g/L
(baseline) group, mean serum iron concentrations in the other
groups increased markedly from 25% to 842%, which is consis-
tent with increasing hemolysis (Figure 2B). Zinc concentrations
were then assessed to determine which hemolysis group would
reach the target of 5% above baseline SZC. The 0.2–0.5- and
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0.5–1-g/L hemolysis groups had the same mean SZC as the
baseline group, whereas the 2.5–5- and 5–10-g/L hemolysis
groups had mean SZCs 12% and 28% higher than baseline,
respectively (Figure 2C). The 1–2.5-g/L hemolysis group showed
the closest match to the 5% target, with a mean SZC of 6% over
baseline, although this did not reach significance. However, the
measured 6% increase in mean SZC for the 1–2.5-g/L group is
consistent with the trend of elevated SZC in the groups with
greater hemolysis and was consistent with a 5% increase in zinc
concentrations from 1 g hemoglobin/L hemolysates as deter-
mined above. It is important to note that this analysis is based on
the assumption that mean SZC would be the same between all
groups without the addition of hemolysis, which was not
possible to test independently.
FIGURE 1 Effects of hemolysis on plasma iron and
zinc concentrations in vitro. The trace mineral concen-
tration increased as a function of hemolysis as indicated
by the hemoglobin concentration. (A) Plasma iron
concentrations increased with the addition of hemoly-
sate to nonhemolyzed plasma. Values are means 6
SDs, n = 60. Data were fit to a linear function (solid line,
R2 = 0.918) with a 95% confidence band (dashed line)
also shown. The inset shows data on a log10 scale. (B)
Plasma zinc concentrations increased with the addition of
hemolysate to nonhemolyzed plasma at;1 g hemoglobin/L.
Values are means 6 SDs, n = 60. Data were fit to a
linear function (solid line, R2 = 0.698) with a 95%
confidence band (dashed line) also shown. The inset
shows data on a log10 scale. (C) Iron and zinc concen-
trations were plotted for each plasma sample. Gray
shading indicates the clinical reference range for plasma
iron and zinc concentration as indicated (20). Values are
means 6 SDs, n = 60. Data were fit to a linear function
(solid line, R2 = 0.274).
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Evaluation of hemoglobin concentrations to assess he-
molysis in plasma or serum. Several approaches were used to
determine hemoglobin concentrations in plasma or serum.
Chemical detection of hemoglobin has a typical minimum
detection limit of ;0.01 g/L (24), but these assays are often not
convenient for large, multicenter, and/or field studies. One
alternative approach is the use of a simple color scale to estimate
the degree of hemolysis (Figure 3). The apparent color of 1 g
hemoglobin/L in plasma or serum is distinctly orange-red, which
is similar to an RGB color model value of 249, 125, 63. If greater
precision is needed, direct measurement of the absorption of
plasma or serum samples was found to be sufficient to detect 1 g
hemoglobin/L, without chemical modification of the constituent
hemoglobin (Supplemental Figure 1). Hemoglobin has several
FIGURE 2 Effects of hemolysis on serum iron and zinc
concentrations in a population nutritional survey. (A) Iron
and zinc concentrations were plotted for each serum
sample. Gray shading indicates the clinical reference
range for serum iron and zinc concentrations as indi-
cated (20). Data were fit to a linear function (solid line,
R2 = 0.104). (B) Serum iron concentrations increased as a
function of hemolysis range grouping on the basis of
hemoglobin concentration. Values are means 6 SDs,
n = 46–289. (C) Serum zinc concentrations increased as a
function of hemolysis range grouping on the basis of
hemoglobin concentration. Values are means 6 SDs,
n = 46–288. *P , 0.05. Hb, hemoglobin.
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major absorption peaks with varying sensitivity. However,
plasma or serum had a significant absorbance at the smaller
wavelength peaks, so the absorbance peak at 540 nm is
recommended. The absorbance value for 1 g hemoglobin/L at
540 nm was 0.16 6 0.04.
Discussion
Hemolysis can affect the constituent analysis of serum or
plasma. For zinc measurement, this can be a concern because the
zinc concentration in erythrocytes is 10–20 times that of plasma
or serum (8, 10, 20). Many studies for measuring PZC and SZC
simply warn the investigator to avoid hemolysis, without
providing specific quantitative metrics. Underestimating the
impact of hemolysis can result in the inclusion of samples
containing plasma or serum contaminated with inflated amounts
of zinc, which adds noise to the analysis of zinc status in a
population. Overestimating the impact of hemolysis can result in
the rejection of samples that are perfectly acceptable for zinc
measurement, and thus losing study power and introducing
sampling bias. Having a clear threshold of hemolysis for
measuring PZC and SZC is important for evaluating zinc status
and response to zinc nutrition interventions.
In this study, we approached this problem in 3 different ways:
1) theoretical calculation by using standard hematologic values
and mineral concentrations, 2) controlled addition of hemolysate
in vitro, and 3) correlation of zinc concentration to hemolysis
levels in samples from a large population study. All 3 approaches
indicated a similar value of ;1 g hemoglobin/L as the level of
hemolysis that increased PZC and SZC by;5%. This target level
of increased zinc was chosen because the analytical techniques
that measure PZC and SZC, such as AAS or ICP-OES, typically
yield a CV of 5% (25). Therefore, a 5% increase in PZC or SZC
would be a minimum value to reliably detect changes in PZC and
SZC. However, it would be straightforward to adjust these
calculations if a different percentage increase in PZC and SZC
was preferred. For example, the WHO estimates that >1 billion
women and children in developing countries suffer from iron
deficiency and anemia (26); therefore, the concentrations of
erythrocyte hemoglobin and other hematologic values in these
areas are likely to be even lower than the example values used in
this analysis. The degree of hemolysis can be determined by using
the same calculations as above, replacing the specific hematologic
and mineral concentration parameters for the desired study
population.
Several reports measuring PZC and SZC mentioned the
potential confounding effects of hemolysis, yet do not provide
details as to how samples with observable hemolysis were
evaluated. Other studies have stated that hemolyzed samples
were recorded and/or discarded, but do not indicate the level of
hemolysis used for threshold. Only a few studies, to our knowl-
edge, directly investigated the effect of hemolysis on PZC/SZC, but
the methodologies varied and often used descriptive analysis of
hemolysis (e.g., low, moderate, and extensive) without specific
quantitative values (27, 28). Lofberg and Levrl (15) reported no
significant change in SZC in a small study of ‘‘hemolyzed’’
compared with ‘‘unhemolyzed’’ samples, but estimated that a ‘‘1–
2% hemolysis’’ could result in increased zinc. Strand et al. (27)
measured the changes in zinc from hemolyzed samples but with the
use of qualitative categorization (mild, moderate, or extensive)
measured by trained technicians. However, the understanding of
these categories may differ between laboratories.
Measuring hemoglobin concentrations in plasma or serum is
arguably the most convenient way to determine the level of
hemolysis in a blood sample, because the normal concentration
of hemoglobin in plasma or serum is negligible compared with
the amount of hemoglobin released during even mild hemolysis.
There are several ways to measure hemoglobin. The classic
chemical method involves the transformation to methemoglobin
followed by reaction with alkaline potassium cyanide (24).
Improved versions of the chemical method for detecting hemo-
globin are now available that avoid the use of toxic cyanide
compounds and extend the sensitivity of the assay (29). In
addition, point-of-care devices that directly measure hemoglo-
bin in small blood samples are available and now commonly
used in field studies (30). Strengths of the chemical and device-
based measurements include a straightforward protocol and
high sensitivity. Weaknesses of this approach include the
additional time and procedural steps, increased costs, and use of
toxic chemicals for the chemical assays; these complications are
particularly inconvenient for large, multicenter, and/or field
studies. In addition, the high sensitivity of these assays is not
necessary to measure the relatively high threshold level of 1 g
hemoglobin/L.
Therefore, alternative ways to assess hemoglobin concentra-
tion were investigated that might be more amenable for large
and/or field studies of PZC and SZC. Because hemoglobin has
significant absorbance within the visual spectrum, hemoglobin
in plasma or serum can be detected by direct spectrophotometry
without any chemical modifications. This method is less
sensitive than the chemical methods, but is easily able to detect
hemoglobin at 1 g/L. Strengths of this approach include minimal
additional costs, a simple protocol, and a nondestructive method
that allows the plasma or serum to be used for other measure-
ments. Weaknesses of this approach include additional time and
FIGURE 3 Methods to determine hemoly-
sis levels in plasma or serum. A representa-
tion of plasma or serum within increasing
levels of hemolysis is shown. Below the
images are the corresponding Hb concentra-
tions (means 6 SDs; n = 3) and approximate
RGB color model values of the corresponding
plasma or serum. The iron values listed for
the lowest category of hemolysis reflect the
clinical reference range in nonhemolyzed
plasma or serum (0.5–1.8 mg/L) (20).
A540nm, absorbance at 540 nm; Hb, hemoglo-
bin; RGB, red, green, blue; ,DL, below the
detection limit of 0.05 absorbance.
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procedural steps and inability to resolve color variations in
plasma unrelated to hemolysis, such as infection or high
concentrations of bilirubin, carotenoids, or ceruloplasmin (31).
Another proposed way to assess hemoglobin concentration is
to take advantage of the constitutive iron within the hemoglobin
protein. If technologies such as ICP-OES are used to measure
PZC and SZC, then iron concentration can be measured in the
same analytical run. The additional iron added into plasma
or serum by 1 g hemoglobin/L is substantially greater than
endogenous concentrations, and thus might be useful to identify
samples that exceed the hemolysis threshold. Strengths of this
approach include that no additional time, procedural steps, or
costs are needed beyond what is needed to determine PZC and
SZC. Weaknesses of this approach include the inability to
distinguish between hemolysis and elevated iron resulting from
iron supplementation or contamination of samples. In addition,
ICP-OES and similar technologies are not always available to
researchers; other common technologies such as AAS can also
measure iron but require separate analyses with additional
sample material. Furthermore, we found that in the hemolysis
analysis in both the in vitro plasma (Figure 1C) and the
population serum (Figure 2A) samples, there was only a weak
correlation between iron and zinc concentrations in the plasma
or serum. Therefore, we do not recommend iron concentrations
alone as an approach to screen plasma or serum samples for PZC
and SZC analysis.
The final way to estimate hemoglobin concentration is to
visually compare the plasma or serum samples to a hemolysis
color scale, based on the fact that hemoglobin is strongly
colored. This approach has been reported in other publications
(11, 14). Strengths of this approach include that it has no
additional procedural steps or costs. This technique is easy to
use, even for large-population studies, and simple to teach the
technical staff. Weaknesses of this approach include the need for
some additional time and the lack of quantitative hemoglobin
measurement. However, we found that, once trained, technical
staff are able to easily and rapidly identify plasma or serum
samples that exceed the color threshold. To facilitate this
approach, we created a simple card containing a hemolysis index
with identification of our recommended threshold of hemolysis.
This card is available on the International Zinc Nutrition
Consultative Group website (www.izincg.org) and can be
digitally displayed (e.g., on a smartphone or tablet) or printed,
assuming that color-management tools are used to correct for
variance in printer output.
Once the relation between hemolysis and PZC and/or SZC is
clearly defined, there might be interest in a correction factor that
could remove the zinc concentrations originating from erythrocyte
leakage from PZC and SZC calculations. For example, this was a
common approach for the measurement of potassium concentra-
tions in plasma or serum (32). However, we do not recommend
this approach for PZC and SZC due to the substantial variance
found in erythrocyte zinc concentrations, hemoglobin concentra-
tions, and other factors. Recently, this approach has become
increasingly criticized even for the determination of potassium,
which tends to be less variable than PZC and SZC (33).
This study recommends a discrete threshold of hemolysis and
hemoglobin concentration beyond which the plasma or serum
concentrations of zinc could be compromised due to leaching of
erythrocyte zinc stores. This conclusion was reached through a
combination of theoretical calculations, simulated hemolysis
testing in vitro, and analysis of samples from a large field study.
There are many other minerals, vitamins, and enzyme markers
in which plasma or serum concentrations could be compromised
by hemolysis. By using similar approaches to this study, appro-
priate thresholds could be reached for all of these nutrients or
biomarkers.
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